The Dividend Note
The Dividend Note - what are the risks? NXT, MIDW, PGH, MPE (22/03/24)
I review the latest numbers from UK dividend shares that each carry quite different risks - Next, Midwich, Personal Group, and MP Evans.
The Dividend Note
I review the latest numbers from UK dividend shares that each carry quite different risks - Next, Midwich, Personal Group, and MP Evans.
Dividend share reviews
This engineering group can trace its roots back nearly 200 years, but is continuing to invest in new growth opportunities.
The Dividend Note
I review results from five stocks that are relatively new to me - Alfa Financial, TI Fluid Systems, 4imprint, Foresight Solar and Supermarket Income REIT.
The Dividend Note
I review recent results from Robert Walters, Inchcape and Nichols and ask whether they offer value. Plus Spirent Communications.
Podcasts
Paul Hill and I talk about UK shares on our radar and field live questions from listeners! Lots of interesting stocks covered in this discussion.
Portfolio
Eight companies from my portfolio reported in February - I review the good, the bad and the ugly.
The Dividend Note
I review the latest results from Croda International, Bunzl and Spectris, all of which have delivered 30+ years of dividend growth. Plus small-cap packaging specialist Macfarlane.
Podcasts
Graham Neary, Mark Simpson and I discuss the investment prospects of Hargreaves Lansdown, Close Brothers, Plus500 and Jet2.
The Dividend Note
I review the latest results from FTSE 250 stock Moneysupermarket.com Group and small-cap Wilmington - and also consider the issue of buybacks and the case for a resurgence in dividend investing.
Dividend share reviews
FTSE 100 Diageo (LON:DGE) warned on profits in November and is going through a slow patch. Is this an opportunity to add this quality compounder to my dividend portfolio?
The Dividend Note
I take a look at full-year results from FTSE 100 dividend stocks Coca Cola HBC and Relx. Both of these are possible contenders for my portfolio, at the right price.
The Dividend Note
I drill down into this week's results from AstraZeneca, Renishaw and specialist lender Real Estate Credit Investments.
Disclaimer: All content provided on this website is intended for educational and entertainment purposes only. This website does not provide investment advice or recommendations. You should research all investment decisions yourself and not rely upon information provided on this website. If you are unable to do this you should seek professional advice from a registered financial adviser.